[1] Hwang ST.Mechanisms of T cell homing to skin.Adv Dermatol, 2001,17:211-241.
[2] Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents.J Am Acad Dermatol, 2002,46:1-23.
[3] Aruffo A, Hollenbaugh D.Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease.Curr Opin Immunol, 2001,13:683-686.
[4] Kondo S, Yoneta A, Yazawa H, et al.Downregulation of CXCR-2 but not CXCR-1 expression by human keratinocytes by UVB.J Cell Physiol, 2000,182:366-370.
[5] Vandenbark AA, Morgan E, Bartholomew R, et al.TCR peptide therapy in human autoimmune diseases.Neurochem Res, 2001,26:713-730.
[6] Raychaudhuri SP, Farber EM.Neuroimmunologic aspects of psoriasis.Cutis, 2000,66:357-362.
[7] Schroder JM, Harder J.Human beta-defensin-2.Int J Biochem Cell Biol, 1999,31:645-651.
[8] Nickoloff BJ.Creation of psoriatic plaques:the ultimate tumor suppressor pathway.A new model for an ancient T-cell-mediated skin disease.Viewpoint.J Cutan Pathol, 2001,28:57-64. |
